Inventiva
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
/ 
Frequently asked questions
To buy Inventiva stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Inventiva by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Inventiva is IVA:xpar. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Inventiva has its primary listing on Euronext Paris. You can trade Inventiva with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Inventiva is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Inventiva as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Inventiva.